Article Text

Download PDFPDF

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

About 12% of deaths from cancer among children <15 years old are from neuroblastoma and nearly half of all patients with neuroblastoma have a high-risk phenotype. Standard treatment for high-risk disease is myeloablative therapy with stem-cell rescue followed by treatment of minimal residual disease with isotretinoin but results are unsatisfactory. Now a multicentre US study (New England Journal of Medicine 2010;363:1324–34) has shown that immunotherapy may benefit children with high-risk neuroblastoma. A total of 226 patients with high risk neuroblastoma in remission after myeloablative therapy and stem-cell rescue were randomised to immunotherapy plus isotretinoin or isotretinoin alone. Immunotherapy consisted of the monoclonal antibody, ch14.18, against the disialoganglioside GD2 expressed by all neuroblastomas plus granulocyte-macrophage colony-stimulating factor and interleukin-2. The trial was stopped early because of better results in the immunotherapy group. Overall survival at 2 years was 86% (immunotherapy plus isotretinoin) versus 75% (isotretinoin alone) and 2-year event-free survival 66% versus 46%.

These researchers conclude that more routine use of this immunotherapy regimen for such patients may be beneficial.

In stark contrast to high-risk neuroblastoma, intermediate-risk neuroblastoma has a >80% rate of overall survival with moderately aggressive chemotherapy. A multicentre study (New England Journal of Medicine 2010;363:1313–23) has shown that very high survival rates can be achieved with substantially reduced duration and dosage …

View Full Text